Skip to content

Study · Randomized controlled trial · 2021

5 results

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.

Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S

Science (New York, N.Y.)22 Apr 2021Cited by 362 (Europe PMC)

PMID33888596 (opens in a new tab)PMCIDPMC8550608 (opens in a new tab)DOI10.1126/science.abe9985 (opens in a new tab)PepBankPUB-33888596
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with prediabetes and overweight or obesity, insulin-stimulated glucose disposal increased after NMN but not placebo.

    In plain wordsIn women with prediabetes and overweight or obesity, insulin-stimulated glucose disposal increased after NMN but not placebo.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseInsulin-stimulated glucose disposal
    Study

    n: not reported in source

    Comparator
    Baseline, with no change after placebo treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    Insulin-stimulated glucose disposal, assessed by using the hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling [phosphorylation of protein kinase AKT and mechanistic target of rapamycin (mTOR)] increased after NMN supplementation but did not change after placebo treatment.
    1 context sentence
    Summary · context
    We conducted a 10-week, randomized, placebo-controlled, double-blind trial to evaluate the effect of NMN supplementation on metabolic function in postmenopausal women with prediabetes who were overweight or obese.
  2. 02HumanRandomized controlled trialMechanism

    In postmenopausal women with prediabetes and overweight or obesity, muscle AKT phosphorylation increased after NMN but not placebo.

    In plain wordsIn women with prediabetes and overweight or obesity, muscle AKT phosphorylation increased after NMN but not placebo.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseAKT phosphorylation
    Study

    n: not reported in source

    Comparator
    Baseline, with no change after placebo treatment
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    Insulin-stimulated glucose disposal, assessed by using the hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling [phosphorylation of protein kinase AKT and mechanistic target of rapamycin (mTOR)] increased after NMN supplementation but did not change after placebo treatment.
    1 context sentence
    Summary · context
    We conducted a 10-week, randomized, placebo-controlled, double-blind trial to evaluate the effect of NMN supplementation on metabolic function in postmenopausal women with prediabetes who were overweight or obese.
  3. 03HumanRandomized controlled trialMechanism

    In postmenopausal women with prediabetes and overweight or obesity, muscle mTOR phosphorylation increased after NMN but not placebo.

    In plain wordsIn women with prediabetes and overweight or obesity, muscle mTOR phosphorylation increased after NMN but not placebo.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreasemTOR phosphorylation
    Study

    n: not reported in source

    Comparator
    Baseline, with no change after placebo treatment
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    Insulin-stimulated glucose disposal, assessed by using the hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling [phosphorylation of protein kinase AKT and mechanistic target of rapamycin (mTOR)] increased after NMN supplementation but did not change after placebo treatment.
    1 context sentence
    Summary · context
    We conducted a 10-week, randomized, placebo-controlled, double-blind trial to evaluate the effect of NMN supplementation on metabolic function in postmenopausal women with prediabetes who were overweight or obese.
  4. 04HumanRandomized controlled trialMechanism

    In postmenopausal women with prediabetes and overweight or obesity, NMN increased platelet-derived growth factor receptor β expression.

    In plain wordsIn women with prediabetes and overweight or obesity, NMN increased platelet-derived growth factor receptor β expression.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreasePlatelet-derived growth factor receptor β expression
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    NMN supplementation up-regulated the expression of platelet-derived growth factor receptor β and other genes related to muscle remodeling.
    1 context sentence
    Summary · context
    We conducted a 10-week, randomized, placebo-controlled, double-blind trial to evaluate the effect of NMN supplementation on metabolic function in postmenopausal women with prediabetes who were overweight or obese.
  5. 05HumanRandomized controlled trialMechanism

    In postmenopausal women with prediabetes and overweight or obesity, NMN increased expression of other muscle remodeling genes.

    In plain wordsIn women with prediabetes and overweight or obesity, NMN increased expression of genes related to muscle remodeling.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseMuscle remodeling gene expression
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    NMN supplementation up-regulated the expression of platelet-derived growth factor receptor β and other genes related to muscle remodeling.
    1 context sentence
    Summary · context
    We conducted a 10-week, randomized, placebo-controlled, double-blind trial to evaluate the effect of NMN supplementation on metabolic function in postmenopausal women with prediabetes who were overweight or obese.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT03151239

Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function

Washington University School of Medicinen = 251 Jul 2017 to 30 Jun 2021

Glucose Metabolism Disorders

Trial pageClinicalTrials.govUpdated 14 Jul 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.